-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals only
Professor Yu Hui of the Affiliated Cancer Hospital of Fudan University shared a case of advanced lung cancer with a negative driving gene, and after treatment, the progression-free survival period reached 3 years
I.
Patients volunteered to participate in the CheckMate227 clinical trial
Radiographic changes in the course of treatment
Follow-up CT shows that in November 2019, the original tumor foci changed from hollow to solid, does this mean that the disease progressed after using the double exemption regimen? In recent years, immunotherapy has greatly changed the pattern
In terms of safety, the incidence of adverse events occurred during double exemption regimen therapy was lower, and no new immune-related adverse reactions
↓Come to the class↓
【Tumor long survival "miracle" case set】